Two randomized, double-blind, placebo-controlled, dose-escalation phase 1 studies evaluating BTH1677, a 1, 3–1,6 beta glucan pathogen associated molecular pattern, in healthy volunteer subjects

Overview of attention for article published in Investigational New Drugs, February 2016

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
One of the highest-scoring outputs from this source (#4 of 1,168)
High Attention Score compared to outputs of the same age (98th percentile)
High Attention Score compared to outputs of the same age and source (92nd percentile)

Mentioned by

news: 16 news outlets

Citations

dimensions_citation: 11 Dimensions

Readers on

mendeley: 47 Mendeley

Summary News Dimensions citations

So far, Altmetric has seen 16 news stories from 16 outlets.

Biothera Announces Imprime PGG Positive Safety Findings and Pharmacokinetic Data from Two Phase 1 Studies, as Published in Investigational New Drugs: The Journal of New Anticancer Agents

Bioportfolio, 25 Feb 2016

Imprime PGG (Beta 1,3/1,6 glucan) also has established proof of concept as an immuno-oncology therapy in subsequent single arm…

Biothera Announces Imprime PGG Positive Safety Findings and Pharmacokinetic Data from Two Phase 1 Studies, as Published in Investigational New Drugs: The Journal of New Anticancer Agents

KAIT-TV, 25 Feb 2016

Imprime PGG (Beta 1,3/1,6 glucan) also has established proof of concept as an immuno-oncology therapy in subsequent single arm…

Biothera Announces Imprime PGG Positive Safety Findings and Pharmacokinetic Data from Two Phase 1 Studies, as Published in Investigational New Drugs: The Journal of New Anticancer Agents

KUSI News, 25 Feb 2016

Imprime PGG (Beta 1,3/1,6 glucan) also has established proof of concept as an immuno-oncology therapy in subsequent single arm…

Biothera Announces Imprime PGG Positive Safety Findings and Pharmacokinetic Data from Two Phase 1 Studies, as Published in Investigational New Drugs: The Journal of New Anticancer Agents

WTVM, 25 Feb 2016

Imprime PGG (Beta 1,3/1,6 glucan) also has established proof of concept as an immuno-oncology therapy in subsequent single arm…

Biothera Announces Imprime PGG Positive Safety Findings and Pharmacokinetic Data from Two Phase 1 Studies, as Published in Investigational New Drugs: The Journal of New Anticancer Agents

KCENG12, 25 Feb 2016

Imprime PGG (Beta 1,3/1,6 glucan) also has established proof of concept as an immuno-oncology therapy in subsequent single arm…

Biothera Announces Imprime PGG Positive Safety Findings and Pharmacokinetic Data from Two Phase 1 Studies, as Published in Investigational New Drugs: The Journal of New Anticancer Agents

Mississippi News Now , 25 Feb 2016

Imprime PGG (Beta 1,3/1,6 glucan) also has established proof of concept as an immuno-oncology therapy in subsequent single arm…

Biothera Announces Imprime PGG Positive Safety Findings and Pharmacokinetic Data from Two Phase 1 Studies, as Published in Investigational New Drugs: The Journal of New Anticancer Agents

KPLC 7 News, 25 Feb 2016

Imprime PGG (Beta 1,3/1,6 glucan) also has established proof of concept as an immuno-oncology therapy in subsequent single arm…

News story from Bloomberg on Thursday 25 February 2016

Bloomberg, 25 Feb 2016

Biothera Announces Imprime PGG Positive Safety Findings and Pharmacokinetic Data from Two Phase 1 Studies, as Published in Investigational New Drugs: The Journal of New Anticancer Agents - Press Release

Digital Journal, 25 Feb 2016

EAGAN, Minn.--(Business Wire)--Biothera Pharmaceuticals Inc. today announced the peer-reviewed publication of positive safety…

Biothera Announces Imprime PGG Positive Safety Findings and Pharmacokinetic Data from Two Phase 1 Studies, as Published in Investigational New Drugs: The Journal of New Anticancer Agents

CNBC, 25 Feb 2016

Imprime PGG (Beta 1,3/1,6 glucan) also has established proof of concept as an immuno-oncology therapy in subsequent single arm…

Biothera Announces Imprime PGG Positive Safety Findings and Pharmacokinetic Data from Two Phase 1 Studies, as Published in Investigational New Drugs: The Journal of New Anticancer Agents

Minyanville: Finance , 25 Feb 2016

Positive safety data from two phase 1 studies with Biothera Pharmaceutical's immunotherapy Imprime PGG were published in…

Biothera Announces Imprime PGG Positive Safety Findings and Pharmacokinetic Data from Two Phase 1 Studies, as Published in Investigational New Drugs: The Journal of New Anticancer Agents

Yahoo! Finance USA, 25 Feb 2016

Imprime PGG (Beta 1,3/1,6 glucan) also has established proof of concept as an immuno-oncology therapy in subsequent single arm…

Biothera Announces Imprime PGG Positive Safety Findings and Pharmacokinetic Data from Two Phase 1 Studies, as Published in Investigational New Drugs: The Journal of New Anticancer Agents

Business Wire, 25 Feb 2016

EAGAN, Minn.--( BUSINESS WIRE )--Biothera Pharmaceuticals Inc. today announced the peer-reviewed publication of positive safety…

Biothera Announces Imprime PGG Positive Safety Findings and Pharmacokinetic Data from Two Phase 1 Studies, as Published in Investigational New Drugs: The Journal of New Anticancer Agents

Stock Nod: Quotes, 25 Feb 2016

. today announced the peer-reviewed publication of positive safety and pharmacokinetic results from two randomized, double-blind…

Biothera Announces Imprime PGG Positive Safety Findings and Pharmacokinetic Data from Two Phase 1 Studies, as Published in Investigational New Drugs: The Journal of New Anticancer Agents

Equities.com, 25 Feb 2016

Imprime PGG (Beta 1,3/1,6 glucan) also has established proof of concept as an immuno-oncology therapy in subsequent single arm…

Biothera Announces Imprime PGG Positive Safety Findings And Pharmacokinetic Data From Two Phase 1 Studies, As Published In /i>

Biospace, 25 Feb 2016

Imprime PGG (Beta 1,3/1,6 glucan) also has established proof of concept as an immuno-oncology therapy in subsequent single arm…